About vir biotechnology inc. - VIR
Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.
VIR At a Glance
Vir Biotechnology, Inc.
1800 Owens Street
San Francisco, California 94158
| Phone | 1-415-906-4324 | Revenue | 68.56M | |
| Industry | Biotechnology | Net Income | -437,987,000.00 | |
| Sector | Health Technology | Employees | 367 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
VIR Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 12.184 |
| Price to Book Ratio | 1.099 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.017 |
| Enterprise Value to Sales | 6.771 |
| Total Debt to Enterprise Value | 0.211 |
VIR Efficiency
| Revenue/Employee | 186,801.09 |
| Income Per Employee | -1,193,425.068 |
| Receivables Turnover | 19.043 |
| Total Asset Turnover | 0.056 |
VIR Liquidity
| Current Ratio | 5.539 |
| Quick Ratio | 5.539 |
| Cash Ratio | 5.052 |
VIR Profitability
| Gross Margin | 82.925 |
| Operating Margin | -682.683 |
| Pretax Margin | -638.558 |
| Net Margin | -638.875 |
| Return on Assets | -35.776 |
| Return on Equity | -45.727 |
| Return on Total Capital | -50.744 |
| Return on Invested Capital | -41.816 |
VIR Capital Structure
| Total Debt to Total Equity | 12.786 |
| Total Debt to Total Capital | 11.337 |
| Total Debt to Total Assets | 9.547 |
| Long-Term Debt to Equity | 11.637 |
| Long-Term Debt to Total Capital | 10.318 |